Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice

Experimental Physiology

Volumn 101, Issue 4, 2016, Pages 521-539

  Kumfu, Sirinart ^a,b   Chattipakorn, Siriporn C ^a,b   Fucharoen, Suthat ^c   Chattipakorn, Nipon ^a,b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL L TYPE; CASPASE 3; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; EFONIDIPINE; FERROPORTIN; HEPCIDIN; IRON; MALONALDEHYDE; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG; ZIP14 PROTEIN; BENZOIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; DIHYDROPYRIDINE DERIVATIVE; IRON CHELATING AGENT; NITROPHENOL; ORGANOPHOSPHORUS COMPOUND; PYRIDONE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA THALASSEMIA; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; HEART FUNCTION; HEART RATE; HEART WEIGHT; IRON INTAKE; IRON OVERLOAD; IRON OVERLOADLOAD THALASSEMIA; KIDNEY MASS; LIVER WEIGHT; MALE; MITOCHONDRION SWELLING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPLEEN WEIGHT; THALASSEMIA; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; C57BL MOUSE; CARDIOVASCULAR DISEASES; DRUG EFFECTS; HEART; METABOLISM; MITOCHONDRION;

ANIMALS; BENZOATES; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; CARDIOVASCULAR DISEASES; DEFEROXAMINE; DIHYDROPYRIDINES; HEART; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MALONDIALDEHYDE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; NITROPHENOLS; ORGANOPHOSPHORUS COMPOUNDS; PYRIDONES; THALASSEMIA; TRIAZOLES;

EID: 84959256766     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/EP085517     Document Type: Article

References (56)

1. Abboud S & Haile DJ (2000). A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 275, 19906-19912.
2. Bartfay WJ & Bartfay E (2000). Iron-overload cardiomyopathy: evidence for a free radical-mediated mechanism of injury and dysfunction in a murine model. Biol Res Nurs 2, 49-59.
3. Berdoukas V, Farmaki K, Carson S, Wood J & Coates T (2012). Treating thalassemia major-related iron overload: the role of deferiprone. J Blood Med 3, 119-129.
4. Brittenham GM (2011). Iron-chelating therapy for transfusional iron overload. N Engl J Med 364, 146-156.
5. Chelli B, Falleni A, Salvetti F, Gremigni V, Lucacchini A & Martini C (2001). Peripheral-type benzodiazepine receptor ligands: mitochondrial permeability transition induction in rat cardiac tissue. Biochem Pharmacol 61, 695-705.
6. Condorelli G, Roncarati R, Ross J Jr, Pisani A, Stassi G, Todaro M, Trocha S, Drusco A, Gu Y, Russo MA, Frati G, Jones SP, Lefer DJ, Napoli C & Croce CM (2001). Heart-targeted overexpression of caspase3 in mice increases infarct size and depresses cardiac function. Proc Natl Acad Sci USA 98, 9977-9982.
7. Crowe S & Bartfay WJ (2002). Amlodipine decreases iron uptake and oxygen free radical production in the heart of chronically iron overloaded mice. Biol Res Nurs 3, 189-197.
8. Di Lisa F, Blank PS, Colonna R, Gambassi G, Silverman HS, Stern MD & Hansford RG (1995). Mitochondrial membrane potential in single living adult rat cardiac myocytes exposed to anoxia or metabolic inhibition. J Physiol 486, 1-13.
9. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH, Drejer A, Barut B, Zapata A, Law TC, Brugnara C, Lux SE, Pinkus GS, Pinkus JL, Kingsley PD, Palis J, Fleming MD, Andrews NC & Zon LI (2000). Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 403, 776-781.
10. Fleming MD, Romano MA, Su MA, Garrick LM, Garrick MD & Andrews NC (1998). Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. Proc Natl Acad Sci USA 95, 1148-1153.
11. Gao X, Campian JL, Qian M, Sun XF & Eaton JW (2009). Mitochondrial DNA damage in iron overload. J Biol Chem 284, 4767-4775.
12. Gao X, Qian M, Campian JL, Marshall J, Zhou Z, Roberts AM, Kang YJ, Prabhu SD, Sun XF & Eaton JW (2010). Mitochondrial dysfunction may explain the cardiomyopathy of chronic iron overload. Free Radic Biol Med 49, 401-407.
13. Gardenghi S, Ramos P, Follenzi A, Rao N, Rachmilewitz EA, Giardina PJ, Grady RW & Rivella S (2010). Hepcidin and Hfe in iron overload in β-thalassemia. Ann N Y Acad Sci 1202, 221-225.
14. Grotto D, Santa Maria LD, Boeira S, Valentini J, Charão MF, Moro AM, Nascimento PC, Pomblum VJ & Garcia SC (2007). Rapid quantification of malondialdehyde in plasma by high performance liquid chromatography-visible detection. J Pharm Biomed Anal 43, 619-624.
15. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL & Hediger MA (1997). Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388, 482-488.
16. Hahalis G, Manolis AS, Gerasimidou I, Alexopoulos D, Sitafidis G, Kourakli A, Körfer R, Koerner MM, Vagenakis AG & Zoumbos NC (2001). Right ventricular diastolic function in β-thalassemia major: echocardiographic and clinical correlates. Am Heart J 141, 428-434.
17. Hershko C, Link G, Konijn AM & Cabantchik ZI (2005). Objectives and mechanism of iron chelation therapy. Ann N Y Acad Sci 1054, 124-135.
18. Incharoen T, Thephinlap C, Srichairatanakool S, Chattipakorn S, Winichagoon P, Fucharoen S, Vadolas J & Chattipakorn N (2007). Heart rate variability in β-thalassemic mice. Int J Cardiol 121, 203-204.
19. 0-thalassemia mutation. Genomics 85, 453-461.
20. Jamsai D, Zaibak F, Vadolas J, Voullaire L, Fowler KJ, Gazeas S, Peters H, Fucharoen S, Williamson R & Ioannou PA (2006). A humanized BAC transgenic/knockout mouse model for HbE/β-thalassemia. Genomics 88, 309-315.
21. Kardelen F, Tezcan G, Akcurin G, Ertug H & Yesilipek A (2008). Heart rate variability in patients with thalassemia major. Pediatr Cardiol 29, 935-939.
22. 2+ channel blockade prevents sudden death in mice with heart failure. Circulation 120, 743-752.
23. Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras D & Keren A (2010). β-Thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ Heart Fail 3, 451-458.
24. Kumfu S, Chattipakorn S, Chinda K, Fucharoen S & Chattipakorn N (2012a). T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice. Eur J Haematol 88, 535-548.
25. Kumfu S, Chattipakorn S, Fucharoen S & Chattipakorn N (2012b). Mitochondrial calcium uniporter blocker prevents cardiac mitochondrial dysfunction induced by iron overload in thalassemic mice. Biometals 25, 1167-1175.
26. Kumfu S, Chattipakorn S, Srichairatanakool S, Settakorn J, Fucharoen S & Chattipakorn N (2011). T-type calcium channel as a portal of iron uptake into cardiomyocytes of beta-thalassemic mice. Eur J Haematol 86, 156-166.
27. Lee DW, Lee TK, Cho IS, Park HE, Jin S, Cho HJ, Kim SH, Oh S & Kim HS (2011). Creation of myocardial fibrosis by transplantation of fibroblasts primed with survival factors. Am J Physiol Heart Circ Physiol 301, H1004-H1014.
28. Lekawanvijit S & Chattipakorn N (2009). Iron overload thalassemic cardiomyopathy: iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity. Can J Cardiol 25, 213-218.
29. Levi S & Rovida E (2009). The role of iron in mitochondrial function. Biochim Biophys Acta 1790, 629-636.
30. Lips DJ, van der Nagel T, Steendijk P, Palmen M, Janssen BJ, van Dantzig JM, de Windt LJ & Doevendans PA (2004). Left ventricular pressure-volume measurements in mice: comparison of closed-chest versus open-chest approach. Basic Res Cardiol 99, 351-359.
31. 2+ influx. Mol Pharmacol 82, 1194-1204.
32. Matsumura T, Furuichi H, Izumi J, Suda H, Ito S, Takei M, Nishi N, Mori T, Tanaka Y & Kurimoto T (1995). [Effect of efonidipine hydrochloride, a calcium channel blocker, on the experimental cerebral ischemia/anoxia]. Nippon Yakurigaku Zasshi 105, 437-446.
33. Murphy CJ & Oudit GY (2010). Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail 16, 888-900.
34. Musumeci M, Maccari S, Sestili P, Massimi A, Corritore E, Marano G & Catalano L (2013). The C57BL/6 genetic background confers cardioprotection in iron-overloaded mice. Blood Transfus 11, 88-93.
35. Nam H, Wang CY, Zhang L, Zhang W, Hojyo S, Fukada T & Knutson MD (2013). ZIP14 and DMT1 in the liver, pancreas, and heart are differentially regulated by iron deficiency and overload: implications for tissue iron uptake in iron-related disorders. Haematologica 98, 1049-1057.
36. Nemeth E, Preza GC, Jung CL, Kaplan J, Waring AJ & Ganz T (2006). The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood 107, 328-333.
37. Novalija E, Kevin LG, Eells JT, Henry MM & Stowe DF (2003). Anesthetic preconditioning improves adenosine triphosphate synthesis and reduces reactive oxygen species formation in mitochondria after ischemia by a redox dependent mechanism. Anesthesiology 98, 1155-1163.
38. 2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 9, 1187-1194.
39. Pacher P, Nagayama T, Mukhopadhyay P, Bátkai S & Kass DA (2008). Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 3, 1422-1434.
40. Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, Elalfy MS, Sutcharitchan P, Li CK, Ibrahim H, Viprakasit V, Kattamis A, Smith G, Habr D, Domokos G, Roubert B & Taher A (2010). Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood 115, 2364-2371.
41. Poggiali E, Cassinerio E, Zanaboni L & Cappellini MD (2012). An update on iron chelation therapy. Blood Transfus 10, 411-422.
42. Qu Y & Boutjdir M (2001). Gene expression of SERCA2a and L- and T-type Ca channels during human heart development. Pediatr Res 50, 569-574.
43. Rebouche CJ, Wilcox CL & Widness JA (2004). Microanalysis of non-heme iron in animal tissues. J Biochem Biophys Methods 58, 239-251.
44. Richardson DR, Lane DJ, Becker EM, Huang ML, Whitnall M, Suryo Rahmanto Y, Sheftel AD & Ponka P (2010). Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc Natl Acad Sci USA 107, 10775-10782.
45. 2+ uptake during simulated ischemia does not affect permeability transition pore opening upon simulated reperfusion. Cardiovasc Res 71, 715-724.
46. Rutjanaprom W, Kanlop N, Charoenkwan P, Sittiwangkul R, Srichairatanakool S, Tantiworawit A, Phrommintikul A, Chattipakorn S, Fucharoen S & Chattipakorn N (2009). Heart rate variability in beta-thalassemia patients. Eur J Haematol 83, 483-489.
47. Singh B, Arora S, Agrawal P & Gupta SK (2011). Hepcidin: a novel peptide hormone regulating iron metabolism. Clin Chim Acta 412, 823-830.
48. Singh S, Hider RC & Porter JB (1990). A direct method for quantification of non-transferrin-bound iron. Anal Biochem 186, 320-323.
49. Surinkaew S, Kumphune S, Chattipakorn S & Chattipakorn N (2013). Inhibition of p38 MAPK during ischemia, but not reperfusion, effectively attenuates fatal arrhythmia in ischemia/reperfusion heart. J Cardiovasc Pharmacol 61, 133-141.
50. Thummasorn S, Kumfu S, Chattipakorn S & Chattipakorn N (2011). Granulocyte-colony stimulating factor attenuates mitochondrial dysfunction induced by oxidative stress in cardiac mitochondria. Mitochondrion 11, 457-466.
51. 2+ channel modifiers: possible implications in iron overload. Circ Res 84, 1302-1309.
52. van Acker FA, Boven E, Kramer K, Haenen GR, Bast A & van der Vijgh WJ (2001). Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity. Clin Cancer Res 7, 1378-1384.
53. Wang Y, Wu M, Al-Rousan R, Liu H, Fannin J, Paturi S, Arvapalli RK, Katta A, Kakarla SK, Rice KM, Triest WE & Blough ER (2011). Iron-induced cardiac damage: role of apoptosis and deferasirox intervention. J Pharmacol Exp Ther 336, 56-63.
54. Wood JC, Enriquez C, Ghugre N, Otto-Duessel M, Aguilar M, Nelson MD, Moats R & Coates TD (2005). Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann N Y Acad Sci 1054, 386-395.
55. Zorov DB, Juhaszova M & Sollott SJ (2006). Mitochondrial ROS-induced ROS release: an update and review. Biochim Biophys Acta 1757, 509-517.
56. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG & Terzoli S (1989). Survival and causes of death in thalassaemia major. Lancet 2, 27-30.